Literature DB >> 17007222

Is cannabis use a contributory cause of psychosis?

Louisa Degenhardt1, Wayne Hall.   

Abstract

OBJECTIVE: To assess whether cannabis use in adolescence and young adulthood is a contributory cause of schizophreniform psychosis in that it may precipitate psychosis in vulnerable individuals.
METHOD: We reviewed longitudinal studies of adolescents and young adults that examined the relations between self-reported cannabis use and the risk of diagnosis with a psychosis or of reporting psychotic symptoms. We also reviewed studies that controlled for potential confounders, such as other forms of drug use and personal characteristics that predict an increased risk of psychosis. We assessed evidence for the biological plausibility of a contributory causal relation.
RESULTS: Evidence from 6 longitudinal studies in 5 countries shows that regular cannabis use predicts an increased risk of a schizophrenia diagnosis or of reporting symptoms of psychosis. These relations persisted after controlling for confounding variables, such as personal characteristics and other drug use. The relation did not seem to be a result of cannabis use to self-medicate symptoms of psychosis. A contributory causal relation is biologically plausible because psychotic disorders involve disturbances in the dopamine neurotransmitter systems with which the cannabinoid system interacts, as demonstrated by animal studies and one human provocation study.
CONCLUSION: It is most plausible that cannabis use precipitates schizophrenia in individuals who are vulnerable because of a personal or family history of schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 17007222     DOI: 10.1177/070674370605100903

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  28 in total

Review 1.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

Review 3.  Epidemiology of schizophrenia: review of findings and myths.

Authors:  Erick L Messias; Chuan-Yu Chen; William W Eaton
Journal:  Psychiatr Clin North Am       Date:  2007-09

4.  Psychoses, PTSD, and depression in Somali refugees in Minnesota.

Authors:  Jerome Kroll; Ahmed Ismail Yusuf; Koji Fujiwara
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-03-31       Impact factor: 4.328

Review 5.  The adverse effects of cannabinoids: implications for use of medical marijuana.

Authors:  Louisa Degenhardt; Wayne D Hall
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

6.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

7.  Adolescent cannabis use increases risk for cocaine-induced paranoia.

Authors:  Rasmon Kalayasiri; Joel Gelernter; Lindsay Farrer; Roger Weiss; Kathleen Brady; Ralitza Gueorguieva; Henry R Kranzler; Robert T Malison
Journal:  Drug Alcohol Depend       Date:  2009-11-26       Impact factor: 4.492

Review 8.  Cannabis controversies: how genetics can inform the study of comorbidity.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

9.  Bidirectional Associations Between Cannabis Use and Depressive Symptoms From Adolescence Through Early Adulthood Among At-Risk Young Men.

Authors:  Sean R Womack; Daniel S Shaw; Chelsea M Weaver; Erika E Forbes
Journal:  J Stud Alcohol Drugs       Date:  2016-03       Impact factor: 2.582

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.